12:00 AM
 | 
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tysabri natalizumab regulatory update

Biogen and partner Elan said FDA and EMA accepted for review regulatory applications to expand the label of multiple sclerosis drug Tysabri natalizumab. The partners are seeking approval for Tysabri as first-line treatment for relapsing forms of MS in anti-JC virus (JCV) antibody-negative patients. Elan said the PDUFA date for...

Read the full 229 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >